BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 50%* for Big Cap Pro

1 year 30%, 2 years 40% and *3 years 50%

*Across 3 years $2276.64 only $1138.32

ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,032.38
      0.56%
      US Tech 100
      20,389.60
      0.88%
      Dow Jones
      44,910.65
      0.42%
      Brent Oil
      71.98
      0.00%
      Bitcoin
      96,953.30
      0.54%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Belite Bio Inc (BLTE)

      7. Belite Bio Inc (BLTE) News

      Belite Bio Inc

      Belite Bio Inc (BLTE)

      NASDAQ
      63.26
      -4.18
      (-6.20%)
      Closed December 01 4:00PM
      Delayed by 15 minutes
      63.26
      0.00
      (0.00%)
      After Hours: 5:00PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      BLTE News

      Official News Only

      Form 144 - Report of proposed sale of securities
      Edgar (US Regulatory)
      November 20 2024
      BLTE (-6.20%)

      Form 144 - Report of proposed sale of securities
      Edgar (US Regulatory)
      November 19 2024
      BLTE (-6.20%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      November 04 2024
      BLTE (-6.20%)

      Form 144/A - Report of proposed sale of securities: [Amend]
      Edgar (US Regulatory)
      October 08 2024
      BLTE (-6.20%)

      Form 144/A - Report of proposed sale of securities: [Amend]
      Edgar (US Regulatory)
      October 08 2024
      BLTE (-6.20%)

      Form 144 - Report of proposed sale of securities
      Edgar (US Regulatory)
      October 03 2024
      BLTE (-6.20%)

      Form 144 - Report of proposed sale of securities
      Edgar (US Regulatory)
      October 03 2024
      BLTE (-6.20%)

      Form S-8 - Securities to be offered to employees in employee benefit plans
      Edgar (US Regulatory)
      October 01 2024
      BLTE (-6.20%)

      BLTE Discussion

      View Posts
      Monksdream Monksdream 3 months ago
      BLTE will it break out
      👍️0
      conix conix 2 years ago
      Short Interest for BLTE--Up 30%

      https://www.etfdailynews.com/2022/09/17/short-interest-in-belite-bio-inc-nasdaqblte-expands-by-30-1/
      👍️0
      conix conix 2 years ago
      BLTE News

      https://seekingalpha.com/news/3875434-blte-stock-gains-as-pivotal-trial-for-lead-asset-starts-in-us
      👍️0
      conix conix 2 years ago
      'Novel Approach For Retinal Disease Needs' Stock Belite Bio Has 70% Potential Upside According To This Analyst

      Vandana Singh

      Mon, August 1, 2022

      HC Wainwright initiated coverage on Belite Bio Inc (NASDAQ: BLTE) with a Buy rating and price target of $58 per ADS.

      Belite Bio is focused on developing a novel once-daily oral drug for the treatment of Stargardt disease (STGD1)—a rare inherited juvenile-onset form of macular degeneration.

      The lead drug candidate is LBS-008 (or Tinlarebant).

      HC Wainwright says that as LBS-008 is administered orally once a day, it could be adopted rapidly by ophthalmologists and patients once the drug obtains regulatory approval, as the intravitreal injection procedure was found unpleasant.

      "We believe LBS-008 has the potential to be developed as the first and best-in-class oral drug for the treatment of STGD1," the analyst writes.

      The analyst expects the Phase 2 portion to report 1-year data in 2H22.

      Meanwhile, the company has initiated a Phase 3 trial of LBS-008 in adolescent STGD1 in 1H22, slated to enroll approximately 60 patients. Enrollment for Phase 3 trial to complete in mid-2023.
      👍️0
      conix conix 3 years ago
      Belite Bio stock soars 65% in wake of strong IPO performance

      May 03, 2022 12:30 PM ETBLTEBy: Val Kennedy, SA News Editor

      IPO Initial Public Offering

      Mikko Lemola/iStock via Getty Images

      Belite Bio (BLTE) stock soared 65% on Tuesday on the heels of a strong performance last Friday following its $36M initial public offering.

      Shares of the ophthalmology drug developer opened at $10.60, recently changing hands at $14.70, up 65%, at approximately $12.05 p.m. ET.

      BLTE held its IPO on April 29, offering 6 million American Depositary Shares at $6 per ADS. Underwriters were granted an option to buy up to 900k additional shares ADSs at the public price. The company’s principal stockholder, Taiwan’s Lin BioScience, agreed to buy around $15M of the offering.

      The stock rocketed following the IPO on Friday, reaching a session high of $17.50 before closing at $10.59, up 77% over its offering price. The stock slid 16% on Monday.

      BLTE has been focused on developing treatments for eye and metabolic diseases. The company plans to use proceeds from the IPO in part to fund Phase 3 clinical testing for its drug candidate LBS-008 for Stargardt disease and further development of the product for the treatment of dry age-related macular degeneration.
      👍️0
      conix conix 3 years ago
      Great news

      https://www.morningstar.com/news/dow-jones/202205038965/belite-bio-shares-jump-47-after-fast-track-designation-for-lbs-008-treatment-for-stargardt-disease
      👍️0

      Your Recent History

      NASDAQ
      BLTE
      Belite Bio
      BIT
      SPDA
      Exchange Traded Fund Ubs...
      LSE
      BIS
      BINA
      WANUSDT
      WanCoin
      Delayed Upgrade Clock